Andreas Pinter

6.5k total citations · 2 hit papers
158 papers, 3.1k citations indexed

About

Andreas Pinter is a scholar working on Immunology, Dermatology and Physiology. According to data from OpenAlex, Andreas Pinter has authored 158 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Immunology, 101 papers in Dermatology and 27 papers in Physiology. Recurrent topics in Andreas Pinter's work include Psoriasis: Treatment and Pathogenesis (96 papers), Dermatology and Skin Diseases (86 papers) and Asthma and respiratory diseases (26 papers). Andreas Pinter is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (96 papers), Dermatology and Skin Diseases (86 papers) and Asthma and respiratory diseases (26 papers). Andreas Pinter collaborates with scholars based in Germany, United States and Canada. Andreas Pinter's co-authors include Kristian Reich, Diamant Thaçi, Andrew Blauvelt, Tsen‐Fang Tsai, Külli Kingo, M. Milutinovic, F. Vanaclocha, R. You, Sophie Hugot and Michael Ziv and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Andreas Pinter

137 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

2015 429 citations Diamant Thaçi, Andrew Blauvelt et al. Journal of the American Academy of Dermatology profile →
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

2021 170 citations Andreas Pinter, Kristian Reich et al. profile →

Peers

Countries citing papers authored by Andreas Pinter

Since Specialization

Citations

This map shows the geographic impact of Andreas Pinter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Pinter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Pinter more than expected).

Fields of papers citing papers by Andreas Pinter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Pinter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Pinter. The network helps show where Andreas Pinter may publish in the future.

Co-authorship network of co-authors of Andreas Pinter

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Pinter. A scholar is included among the top collaborators of Andreas Pinter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Pinter. Andreas Pinter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period 2025 ·British Journal of Dermatology ·Richard B. Warren, Mark Lebwohl, Diamant Thaçi, Melinda Gooderham, Andreas Pinter, C. Paul, Paolo Gisondi, (unknown), Katy White, (unknown), (unknown), Jérémy Lambert, Bruce Strober	3
2	50236 GUIDE trial results after withdrawal in part 3: Long-term remission in patients with psoriasis treated with guselkumab within 15 months from onset of symptoms 2024 ·Journal of the American Academy of Dermatology ·Knut Schäkel, Khusru Asadullah, Andreas Pinter, Peter Weisenseel, Robert Sabat, Matthias Hoffmann, C. Paul, Friedemann Taut, (unknown), (unknown), Kilian Eyerich	1
3	Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials 2024 ·Dermatology and Therapy ·Joseph F. Merola, Alice B. Gottlieb, Andreas Pinter, Boni E. Elewski, Melinda Gooderham, Richard B. Warren, Stefano Piaserico, (unknown), Nancy Cross, Nicola Tilt, (unknown), Ulrich Mrowietz	2
4	Dose escalation of biologic treatment in patients with moderate‐to‐severe psoriasis in Japan 2024 ·Experimental Dermatology ·Yayoi Tada, Ahmed M. Soliman, (unknown), (unknown), Andreas Pinter, Matthew Davis, (unknown), Marric Buessing, L. Puig, Shinichi Imafuku	1
5	Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial 2024 ·Annals of the Rheumatic Diseases ·Laure Gossec, Laura C. Coates, Dafna D. Gladman, Jacob Aelion, (unknown), Andreas Pinter, Joseph F. Merola, Arthur Kavanaugh, (unknown), Rebecca Wang, Michèle Brunori, (unknown), (unknown), Philip J. Mease	4
6	How wound environments trigger the release from Rifampicin-loaded liposomes 2023 ·International Journal of Pharmaceutics ·(unknown), Mukul Ashtikar, Götz Hofhaus, (unknown), (unknown), (unknown), Andreas Pinter, Jennifer Dressman, Matthias G. Wacker	6
7	Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest 2023 ·SKIN The Journal of Cutaneous Medicine ·Kristian Reich, Eric L. Simpson, Richard G. Langley, Richard B. Warren, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Le Gjerum, Anna Carlsson, Melinda Gooderham, Andreas Pinter, (unknown), Andrew Blauvelt	1
8	77 JNJ-77242113 treatment induces strong systemic pharmacodynamic response versus placebo in patients with plaque psoriasis: Results from the phase 2, FRONTIER 1 study 2023 ·Journal of Investigative Dermatology ·Andreas Pinter, Kilian Eyerich, Amy S. Paller, Arun Kannan, (unknown), Diane Horowitz, Sunita Bhagat, Donald Richards, (unknown), Bradford L. McRae, Ya‐Wen Yang, Michelle C. Miller, Cynthia Marie Carver DeKlotz, Robert Bissonnette	1
9	Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan 2023 ·Dermatology and Therapy ·Yayoi Tada, Ahmed M. Soliman, (unknown), (unknown), L. Puig, Matthew Davis, (unknown), Andreas Pinter, Shinichi Imafuku	6
10	42592 Baseline Characteristics and Interim Month 12 mNAPSI Results in Patients with Moderate-to- Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics in the Psoriasis Study of Health Outcomes (PSoHO) 2023 ·Journal of the American Academy of Dermatology ·Alexander Egeberg, Andreas Pinter, Ronald Vender, (unknown), Alan Brnabic, Christopher F. Schuster, (unknown), Catherine Reed, Elisabeth Riedl, L. Puig	1
11	Chronische Entzündungserkrankungen in Deutschland 2023 ·Zeitschrift für Rheumatologie ·Jan Leipe, Renate Schmelz, Gabriela Riemekasten, Diamant Thaçi, Jörg Henes, Knut Schäkel, Andreas Pinter, Michael Sticherling, Joanna Wegner, Stefano Fusco, (unknown), (unknown), (unknown), Holger Bartz, (unknown), Sandra Schmidt, Bimba F. Hoyer	3
12	Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS) 2023 ·British Journal of Dermatology ·Diamant Thaçi, Andreas Pinter, Michael Sebastian, Christian Termeer, Michael Sticherling, Sascha Gerdes, Knut Schäkel, Sven Wegner, (unknown), Holger Bartz, Christian Rausch, Friedemann Taut, Kilian Eyerich	1
13	Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study 2023 ·Journal of the European Academy of Dermatology and Venereology ·Knut Schäkel, Kristian Reich, K. Asadullah, Andreas Pinter, D. Jullien, Peter Weisenseel, C. Paul, (unknown), Sven Wegner, (unknown), (unknown), Yanqing Chen, Julianty Angsana, Monica Leung, Kilian Eyerich	46
14	Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT) 2023 ·Journal of the European Academy of Dermatology and Venereology ·(unknown), Lara Valeska Maul, (unknown), (unknown), (unknown), (unknown), Christina Sorbe, Nikhil Yawalkar, Raphael Micheroli, Alexander Egeberg, Jacob P. Thyssen, Kristine Heidemeyer, Wolf‐Henning Boehncke, Curdin Conrad, Antonio Cozzio, Andreas Pinter, Thomas M. Kündig, Alexander A. Navarini, Julia‐Tatjana Maul	6
15	Speed of clinical improvement in the real‐world setting from patient‐reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks 2023 ·Journal of the European Academy of Dermatology and Venereology ·Adam Reich, Andreas Pinter, Julia‐Tatjana Maul, Ronald Vender, Tiago Torres, Alan Brnabic, (unknown), Catherine Reed, Christopher Schuster, Elisabeth Riedl	6
16	A novel, fixed‐dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30^thEADV Congress 2021 2022 ·Journal of the European Academy of Dermatology and Venereology ·Andreas Pinter, Linda Stein Gold, Adam Reich, Lawrence J. Green, (unknown), Johan Selmer, April W. Armstrong, Anne Danø, Sunil Dhawan, Jordi Galván, Sandra Elkjær Stallknecht, (unknown), Matthias Augustin	4
17	Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial 2021 ·British Journal of Dermatology ·Diamant Thaçi, Kilian Eyerich, Andreas Pinter, Michael Sebastian, Kristina Unnebrink, Simone Rubant, David Williams, Peter Weisenseel	15
18	Efficacy and safety of ixekizumab in a phase III , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( IXORA ‐ PEDS ) 2020 ·British Journal of Dermatology ·Amy S. Paller, Marieke M.B. Seyger, (unknown), Jerry Bagel, Andreas Pinter, Jennifer Clay Cather, Stuart Keller, (unknown), Renata Gontijo Lima, Gaia Gallo, (unknown), Emily Edson‐Heredia, Lü Li, (unknown), Kim Papp, (unknown)	69
19	A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial* 2020 ·British Journal of Dermatology ·Andrew Blauvelt, C. Leonardi, Boni E. Elewski, Jeffrey Crowley, Lyn Guenther, Melinda Gooderham, Richard G. Langley, Ronald Vender, Andreas Pinter, C.E.M. Griffiths, Yayoi Tada, Hany Elmaraghy, Renata Gontijo Lima, Gaia Gallo, L. Renda, Russel Burge, (unknown), Baojin Zhu, Kim Papp, (unknown)	73
20	Interleukin‐17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases 2019 ·The Journal of Dermatology ·Andreas Pinter, Dagmar Wilsmann‐Theis, Wiebke K. Peitsch, Rotraut Mößner	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact